Floatz logo

Ispinesib

Recurrent Childhood Visual Pathway and Hypothalamic Glioma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Recurrent Childhood Visual Pathway and Hypothalamic Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Cilengitide
National Cancer Institute (NCI)
Phase 2B
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B
FILGRASTIM
City of Hope Medical Center
Phase 1CCC

View all 20 →

Same molecule, other indications

Ispinesib is also rated in:

breast cancerDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
colon carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →